{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:35Z","timestamp":1790916815852,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":202,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101333","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:56:52Z","timestamp":1784883412000},"page":"101333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenic effects of hyperthermia in an experimental model of peritoneal metastases of colorectal cancer enhance tumor susceptibility to immunotherapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Michael","family":"Tasker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Tome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Uzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-2372","authenticated-orcid":false,"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101333_bib0001","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101333_bib0002","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0003","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1245\/s10434-013-3223-z","article-title":"Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database","volume":"21","author":"Bartlett","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0004","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamasurg.2013.3640","article-title":"Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program","volume":"149","author":"Jafari","year":"2014","journal-title":"JAMa Surg."},{"key":"10.1016\/j.ctarc.2026.101333_bib0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101333_bib0007","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0008","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1245\/s10434-022-13025-7","article-title":"PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a Murine model","volume":"30","author":"Geva","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109829","article-title":"Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin alpha1","volume":"116","author":"Nevo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101333_bib0011","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2026.101333_bib0014","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2026.101333_bib0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101333_bib0016","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/02656736.2022.2076292","article-title":"Systematic review of the registered clinical trials for oncological hyperthermia treatment","volume":"39","author":"Peeters","year":"2022","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.ctarc.2026.101333_bib0017","first-page":"1840","article-title":"Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug","volume":"44","author":"Koga","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101333_bib0018","first-page":"4081","article-title":"Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats","volume":"40","author":"Shiu","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101333_bib0019","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","article-title":"The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by peritoneal surface oncology group international (PSOGI)","volume":"47","author":"van de Vlasakker","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101333_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110080","article-title":"The Mitomycin versus Oxaliplatin debate on HIPEC in colorectal cancers - an updated systematic review and meta-analysis","volume":"51","author":"Kazi","year":"2025","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:57:03Z","timestamp":1790913423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"alternative-id":["S2468294226002443"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101333","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenic effects of hyperthermia in an experimental model of peritoneal metastases of colorectal cancer enhance tumor susceptibility to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101333"}}